Washington Drug Letter

Aug. 1, 2011 | Vol. 43 No. 30

Pfizer to Change Chantix Label to Show Cardiovascular Risks

The FDA is asking Pfizer to update the label of its popular quit-smoking drug Chantix to include additional safety risks, including heart attack, for patients with cardiovascular disease.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Lawmakers Say Gluten Should Be Noted On Drug Labels FDA Seeks Scientific Evidence for Limiting Opioid Prescriptions, Use Generic Labels Don’t Match Brands 78 Percent of the Time, Study Finds Senator Questions the Status of 2008 Proposed Rule on Pregnancy Risk Labeling

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.